Crestline Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sana Biotechnology
SANA
|
+$72.8M |
| 2 |
Petrobras Class A
PBR.A
|
+$20.9M |
| 3 |
Ameriprise Financial
AMP
|
+$11.4M |
| 4 |
MetLife
MET
|
+$10.1M |
| 5 |
Wells Fargo
WFC
|
+$7.59M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Denali Therapeutics
DNLI
|
+$114M |
| 2 |
Micron Technology
MU
|
+$7.77M |
| 3 |
UDR
UDR
|
+$5.92M |
| 4 |
Equitable Holdings
EQH
|
+$4.95M |
| 5 |
Lam Research
LRCX
|
+$4.46M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 61.94% |
| 2 | Financials | 15.37% |
| 3 | Miscellaneous | 5.4% |
| 4 | Materials | 5.33% |
| 5 | Technology | 3.84% |
Similar funds
Crestline Management's Q2 2021 Portfolio in Review
As of Q2 2021, Crestline Management held 232 positions worth $1.16B, up 47% from $788M the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Crestline Management deployed $137M of net new capital in Q2 2021, opening 129 new positions and adding to 24 existing holdings. Its largest new stake was Sana Biotechnology: 3,210,937 shares worth $63.1M.
By sector, the portfolio is most concentrated in Healthcare at 62% of assets, down from 72% a quarter earlier, followed by Financials and Miscellaneous.
On the sell side, the largest reduction was Denali Therapeutics, an estimated $114M trimmed.
- Crestline Management's largest Q2 2021 buy was Sana Biotechnology: 3,210,937 shares worth $63.1M.
- Crestline Management added most to Travelers Companies in Q2 2021, an estimated $6.82M increase.
- Crestline Management's biggest Q2 2021 reduction was Denali Therapeutics, cutting an estimated $114M.
- Crestline Management fully exited Micron Technology in Q2 2021, selling an estimated $7.77M.
- Crestline Management's ten largest holdings make up 68% of its $1.16B portfolio in Q2 2021.
- Crestline Management opened 129 new positions and closed 56 in Q2 2021.
- Crestline Management's portfolio value rose 47% quarter-over-quarter to $1.16B.
Based on Crestline Management's 13F filing for Q2 2021, filed 13 Aug 2021.